Hisham Alshadfan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hisham Alshadfan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Hyder Mirghani
Department of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia
3 shared publications- Muhammad Nazrul Somchit
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia
3 shared publications - Hyder Osman Mirghani
Department of Internal Medicine, Faculty of Medicine, University of Tabuk, Saudi Arabia
2 shared publications Mansuor Alanazi
Department of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia
2 shared publications- Mohammad Zubair
Department of Medical Microbiology, Faculty of Medicine, University of Tabuk, Tabuk, Kingdom of Saudi Arabia
2 shared publications Muhammad Nazrul Hakim Abdullah
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
2 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e46320
Comparative effectiveness of immediate-release and extended-release metformin on gastrointestinal tolerability, quality of life, and treatment satisfaction: A prospective cohort study
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e46320
Open AccessComparative effectiveness of immediate-release and extended-release metformin on gastrointestinal tolerability, quality of life, and treatment satisfaction: A prospective cohort study
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-19
Antimicrobial and Anti-Biofilm Properties of Ma’in Hot Springs Targeting Bacteria Isolated from Diabetic Foot Ulcers
Diabetic foot ulcers (DFUs) are a serious complication of diabetes, which is worsened by biofilm-forming bacterial infections that can contribute to antibiotic resistance and delayed wound healing. This study explores the antimicrobial and anti-biofilm properties of Ma’in Hot Springs Water (MHSW) against Staphylococcus aureus and Pseudomonas aeruginosa which are associated with DFU. The chemical composition of MHSW was determined using LC-MS, UV-Vis spectroscopy, and heavy metal profiling. Antimicrobial efficacy was determined through minimum inhibitory concentration (MIC) determination, bacterial growth kinetics, and biofilm inhibition assays. The results demonstrated a dose-dependent antibacterial effect. Biofilm formation, exopolysaccharide production, and bacterial adhesion were reduced in treated samples. Moreover, MHSW disrupted virulence factors such as plasma coagulation and metallo-β-lactamase production. It was also found to be non-cytotoxic. These findings demonstrate the potential of MHSW as an alternative or adjunctive treatment for DFU infections. However, the presence of heavy metals exceeding safety limits requires further investigation to determine their optimal concentration for clinical usage.
- 1 January 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-19
Open AccessAntimicrobial and Anti-Biofilm Properties of Ma’in Hot Springs Targeting Bacteria Isolated from Diabetic Foot Ulcers
Diabetic foot ulcers (DFUs) are a serious complication of diabetes, which is worsened by biofilm-forming bacterial infections that can contribute to antibiotic resistance and delayed wound healing. This study explores the antimicrobial and anti-biofilm properties of Ma’in Hot Springs Water (MHSW) against Staphylococcus aureus and Pseudomonas aeruginosa which are associated with DFU. The chemical composition of MHSW was determined using LC-MS, UV-Vis spectroscopy, and heavy metal profiling. Antimicrobial efficacy was determined through minimum inhibitory concentration (MIC) determination, bacterial growth kinetics, and biofilm inhibition assays. The results demonstrated a dose-dependent antibacterial effect. Biofilm formation, exopolysaccharide production, and bacterial adhesion were reduced in treated samples. Moreover, MHSW disrupted virulence factors such as plasma coagulation and metallo-β-lactamase production. It was also found to be non-cytotoxic. These findings demonstrate the potential of MHSW as an alternative or adjunctive treatment for DFU infections. However, the presence of heavy metals exceeding safety limits requires further investigation to determine their optimal concentration for clinical usage.
- Open Access
- 19 December 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52
Impact of immediate-release versus extended-release metformin on lipid profile and body measurements in saudi patients with type 2 diabetes: a prospective cohort study
Introduction: dyslipidemia and obesity frequently accompany type 2 diabetes, contributing to cardiovascular risk. Metformin, beyond its effects on glycemic control, can also influence lipid metabolism and weight. Immediate-release (IR) and extended-release (XR) metformin may have differential effects on lipid profile and anthropometric measures. The study aimed to compare the effects of metformin IR versus XR on lipid parameters and body measurements in patients with type 2 diabetes in Saudi Arabia. Methods: a prospective 6-month cohort study included 119 newly diagnosed type 2 diabetes patients (62 on metformin IR and 57 on metformin XR) at a Saudi hospital. Fasting lipid profile (T-Chol, TGs, HDL-C, and LDL-C) and body weight/BMI were measured at baseline and after 6 months of metformin treatment. Within-group changes and between-group differences were analysed. Results: both groups showed modest improvements in their lipid profile. Metformin XR use was associated with a greater reduction in total cholesterol (-7.8% vs. -5.8% with IR) and LDL-C (-8.7% vs. -5.7% with IR). After 6 months, mean LDL-C was significantly lower in the XR group (102.3 ± 37.5 mg/dL) compared to the IR group (116.9 ± 36.0 mg/dL, p=0.032). Triglyceride and HDL-C levels changed minimally and were similar between groups. Neither IR nor XR had a significant impact on body weight or BMI: both groups remained essentially weight-neutral (average weight change <1 kg over 6 months). Final mean BMI was 30.4 ± 5.9 kg/m² in IR vs. 29.8 ± 4.7 kg/m² in XR (no significant difference). Conclusion: metformin XR was associated with short-term benefits in reducing total and LDL cholesterol levels compared to IR, likely attributable to more stable plasma drug concentrations that enhance lipid metabolism. Both formulations exhibited similar effects on triglycerides, HDL cholesterol, and body weight, reaffirming metformin's overall neutral impact on weight. These findings suggest that metformin XR may offer a marginal reduction in cardiovascular risk through superior LDL cholesterol lowering, while preserving the weight-neutral profile characteristic of metformin therapy.
- 19 December 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52
Open AccessImpact of immediate-release versus extended-release metformin on lipid profile and body measurements in saudi patients with type 2 diabetes: a prospective cohort study
Introduction: dyslipidemia and obesity frequently accompany type 2 diabetes, contributing to cardiovascular risk. Metformin, beyond its effects on glycemic control, can also influence lipid metabolism and weight. Immediate-release (IR) and extended-release (XR) metformin may have differential effects on lipid profile and anthropometric measures. The study aimed to compare the effects of metformin IR versus XR on lipid parameters and body measurements in patients with type 2 diabetes in Saudi Arabia. Methods: a prospective 6-month cohort study included 119 newly diagnosed type 2 diabetes patients (62 on metformin IR and 57 on metformin XR) at a Saudi hospital. Fasting lipid profile (T-Chol, TGs, HDL-C, and LDL-C) and body weight/BMI were measured at baseline and after 6 months of metformin treatment. Within-group changes and between-group differences were analysed. Results: both groups showed modest improvements in their lipid profile. Metformin XR use was associated with a greater reduction in total cholesterol (-7.8% vs. -5.8% with IR) and LDL-C (-8.7% vs. -5.7% with IR). After 6 months, mean LDL-C was significantly lower in the XR group (102.3 ± 37.5 mg/dL) compared to the IR group (116.9 ± 36.0 mg/dL, p=0.032). Triglyceride and HDL-C levels changed minimally and were similar between groups. Neither IR nor XR had a significant impact on body weight or BMI: both groups remained essentially weight-neutral (average weight change <1 kg over 6 months). Final mean BMI was 30.4 ± 5.9 kg/m² in IR vs. 29.8 ± 4.7 kg/m² in XR (no significant difference). Conclusion: metformin XR was associated with short-term benefits in reducing total and LDL cholesterol levels compared to IR, likely attributable to more stable plasma drug concentrations that enhance lipid metabolism. Both formulations exhibited similar effects on triglycerides, HDL cholesterol, and body weight, reaffirming metformin's overall neutral impact on weight. These findings suggest that metformin XR may offer a marginal reduction in cardiovascular risk through superior LDL cholesterol lowering, while preserving the weight-neutral profile characteristic of metformin therapy.
- Open Access
- 11 December 2025
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 20 (6) , 835-845
Efficacy of immediate-release versus extended-release metformin on glycemic control and insulin resistance in Saudi patients with type 2 diabetes: A prospective cohort study
- 11 December 2025
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 20 (6) , 835-845
Open AccessEfficacy of immediate-release versus extended-release metformin on glycemic control and insulin resistance in Saudi patients with type 2 diabetes: A prospective cohort study
- Open Access
- 1 May 2025
- Published by Learning Gate in Edelweiss Applied Science and Technology
- Vol. 9 (5) , 1882-1892
Validation of the Arabic version of the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2) in Tabuk, Saudi Arabia: A pilot study
Diabetes mellitus is common globally, and the Arab countries are no exception. Oral hypoglycemic agents are major pillars of diabetes management. The Oral Hypoglycemic Agent Questionnaire Version 2 (OHA-Q ver. 2) is unavailable in Arabic. Therefore, the study's goal was to validate the questionnaire for use among patients with diabetes in Saudi Arabia. Thirty patients with diabetes were randomly selected from those attending regular follow-ups at the King Fahd Specialist Hospital - Diabetes Center in Tabuk, Saudi Arabia. The study took place in March and April 2023. A structured questionnaire was utilized, incorporating sociodemographic data and the OHA-Q ver. 2. The questionnaire's validity and reliability were evaluated through forward and backward translation, expert review, and Cronbach's Alpha analysis. The results showed that a total of 30 diabetic patients participated in the questionnaire validation, with 60% being female, a mean age of 51.1 ± 14.056 years, and 94% diagnosed with type 2 diabetes. The internal consistency of the OHA-Q ver. 2 was highest for the "treatment convenience" subscale (0.83) and lowest for "satisfaction" (0.78). The overall content validity score was 0.875, and Cronbach’s Alpha for reliability was 0.88. The Arabic version of the OHA-Q ver. 2 has proven to be a valid and reliable tool for diabetic patients in Arab countries.
- 1 May 2025
- Published by Learning Gate in Edelweiss Applied Science and Technology
- Vol. 9 (5) , 1882-1892
Open AccessValidation of the Arabic version of the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2) in Tabuk, Saudi Arabia: A pilot study
Diabetes mellitus is common globally, and the Arab countries are no exception. Oral hypoglycemic agents are major pillars of diabetes management. The Oral Hypoglycemic Agent Questionnaire Version 2 (OHA-Q ver. 2) is unavailable in Arabic. Therefore, the study's goal was to validate the questionnaire for use among patients with diabetes in Saudi Arabia. Thirty patients with diabetes were randomly selected from those attending regular follow-ups at the King Fahd Specialist Hospital - Diabetes Center in Tabuk, Saudi Arabia. The study took place in March and April 2023. A structured questionnaire was utilized, incorporating sociodemographic data and the OHA-Q ver. 2. The questionnaire's validity and reliability were evaluated through forward and backward translation, expert review, and Cronbach's Alpha analysis. The results showed that a total of 30 diabetic patients participated in the questionnaire validation, with 60% being female, a mean age of 51.1 ± 14.056 years, and 94% diagnosed with type 2 diabetes. The internal consistency of the OHA-Q ver. 2 was highest for the "treatment convenience" subscale (0.83) and lowest for "satisfaction" (0.78). The overall content validity score was 0.875, and Cronbach’s Alpha for reliability was 0.88. The Arabic version of the OHA-Q ver. 2 has proven to be a valid and reliable tool for diabetic patients in Arab countries.
- Open Access
- 18 August 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (3) , 42
Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk
The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with E. coli and Pseudomonas sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with E. coli showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with blaCTX-M being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.
- 18 August 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (3) , 42
Open AccessAntibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk
The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with E. coli and Pseudomonas sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with E. coli showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with blaCTX-M being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.
- Open Access
- 1 July 2023
- Published by International Journal of Pharma and Bio Sciences in International Journal of Life Science and Pharma Research
- p. L173-L181
Metformin Immediate and Extended-Release Adverse Events and Effects on Metabolic Parameters: A Meta-Analysis
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95% CI, -0.14-0.29; 1.34, 95% CI, 0.86-2.08; -0.03, 95% CI, -0.22-0.17; and -0.26, 95% CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95% CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95% CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. Keywords: , , , ,
- 1 July 2023
- Published by International Journal of Pharma and Bio Sciences in International Journal of Life Science and Pharma Research
- p. L173-L181
Open AccessMetformin Immediate and Extended-Release Adverse Events and Effects on Metabolic Parameters: A Meta-Analysis
Metformin is the first-line antidiabetic medication, and face-to-face comparisons between immediate-release and extended-release are scarce. The current meta-analysis aimed to compare metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. We searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar from inception until September 2022. Studies were eligible if they were randomized controlled trials and compared metformin's immediate and extended-release effects on glycemic control, adverse events, and lipid profile. The keywords used were metformin immediate-release, extended-release, glycated hemoglobin, HbA1c, high-density lipoproteins, low-density lipoproteins triglycerides, total cholesterol, adverse effects, and side effects. The retrieved data were exported to an Excel sheet detailing the authors' names, the country of origin of the study, the number of patients and control subjects, and the total number of events in the interventional and control groups. No significant statistical difference was found between metformin immediate-release and metformin extended-release regarding the reduction of HbA1c, overall adverse effects, low-density lipoproteins, and high-density lipoproteins; odd ratio, 0.08, 95% CI, -0.14-0.29; 1.34, 95% CI, 0.86-2.08; -0.03, 95% CI, -0.22-0.17; and -0.26, 95% CI, -1.32-0.80 respectively. Metformin immediate-released reduced total cholesterol better than the extended-release; odd ratio, -2.35, 95% CI, -2.57-2.12. However, a paradox was observed regarding triglycerides (increment on extended-release and reduction with extended-release); odd ratio, -0.36, 95% CI, -0.44-0.28. No significant differences were found between the two formulations except for a better triglyceride reduction and total cholesterol in the immediate-release arm. Keywords: , , , ,